ArticleJournal of computational biology : a journal of computational molecular cell biology2015
Simultaneous inference of cancer pathways and tumor progression from cross-sectional mutation data.
Article in Journal of computational biology : a journal of computational molecular cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A latent variable model for evaluating mutual exclusivity and co-occurrence between driver mutations in cancer.bioRxiv : the preprint server for biology · 2024Article
- Joint inference of exclusivity patterns and recurrent trajectories from tumor mutation trees.Nature communications · 2023Article
- ToMExO: A probabilistic tree-structured model for cancer progression.PLoS computational biology · 2022Article
- Inferring tumor progression in large datasets.PLoS computational biology · 2020Article
- Modelling cancer progression using Mutual Hazard Networks.Bioinformatics (Oxford, England) · 2020Article
- A probabilistic method for leveraging functional annotations to enhance estimation of the temporal order of pathway mutations during carcinogenesis.BMC bioinformatics · 2019Article
- Uncovering the subtype-specific temporal order of cancer pathway dysregulation.PLoS computational biology · 2019Article
- Every which way? On predicting tumor evolution using cancer progression models.PLoS computational biology · 2019Article
- Efficient algorithms to discover alterations with complementary functional association in cancer.PLoS computational biology · 2019Article
- Cancer progression models and fitness landscapes: a many-to-many relationship.Bioinformatics (Oxford, England) · 2018Article
- Computational Methods for Characterizing Cancer Mutational Heterogeneity.Frontiers in genetics · 2017Review
- Computational approaches for the identification of cancer genes and pathways.Wiley interdisciplinary reviews. Systems biology and medicine · 2017Review
- The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.Seminars in cell & developmental biology · 2016Review
- Computational Cancer Biology: An Evolutionary Perspective.PLoS computational biology · 2016Review
- Integrating mutation and gene expression cross-sectional data to infer cancer progression.BMC systems biology · 2016Article
- Identifying restrictions in the order of accumulation of mutations during tumor progression: effects of passengers, evolutionary models, and sampling.BMC bioinformatics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent cancer sequencing studies provide a wealth of somatic mutation data from a large number of patients. One of the most intriguing and challenging questions arising from this data is to determine whether the temporal order of somatic mutations in a cancer follows any common progression. Since we usually obtain only one sample from a patient, such inferences are commonly made from cross-sectional data from different patients. This analysis is complicated by the extensive variation in the somatic mutations across different patients, variation that is reduced by examining combinations of mutations in various pathways. Thus far, methods to reconstruct tumor progression at the pathway level have restricted attention to known, a priori defined pathways. In this work we show how to simultaneously infer pathways and the temporal order of their mutations from cross-sectional data, leveraging on the exclusivity property of driver mutations within a pathway. We define the pathway linear progression model, and derive a combinatorial formulation for the problem of finding the optimal model from mutation data. We show that with enough samples the optimal solution to this problem uniquely identifies the correct model with high probability even when errors are present in the mutation data. We then formulate the problem as an integer linear program (ILP), which allows the analysis of datasets from recent studies with large numbers of samples. We use our algorithm to analyze somatic mutation data from three cancer studies, including two studies from The Cancer Genome Atlas (TCGA) on large number of samples on colorectal cancer and glioblastoma. The models reconstructed with our method capture most of the current knowledge of the progression of somatic mutations in these cancer types, while also providing new insights on the tumor progression at the pathway level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.